Evidence map›Paper›PMID 36248329›Full record

ArticleTranslational lung cancer research2022

Circulating tumor DNA accurately predicts disease progression and genotype alterations in postoperative adjuvant EGFR-TKI resistance: a case report.

Zhen Zeng, Chengwu Liu, Senyi Deng, Feng Lin, Hatim Husain, Mariacarmela Santarpia, Lunxu Liu

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Zhen Zeng *Department of Thoracic Surgery and Institute of Thoracic Tumor, West China Hospital, Sichuan University, Chengdu, China.
Chengwu Liu *Department of Thoracic Surgery and Institute of Thoracic Tumor, West China Hospital, Sichuan University, Chengdu, China.
Senyi DengDepartment of Thoracic Surgery and Institute of Thoracic Tumor, West China Hospital, Sichuan University, Chengdu, China.
Feng LinDepartment of Thoracic Surgery and Institute of Thoracic Tumor, West China Hospital, Sichuan University, Chengdu, China.
Hatim HusainDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Mariacarmela SantarpiaMedical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, Messina, Italy.
Lunxu LiuDepartment of Thoracic Surgery and Institute of Thoracic Tumor, West China Hospital, Sichuan University, Chengdu, China.
Sichuan University · CNUniversity of California, San Diego · USUniversity of Messina · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Circulating tumor DNA (ctDNA) is receiving more and more attention for its role in tumor screening and disease surveillance in cancer patients. However, it is unclear whether ctDNA can be used to predict recurrence and metastasis in patients after radical resection due to the resulting lower tumor burden. The published literature on postoperative ctDNA levels is also currently limited. Case Description: In this article, we report a rare case in which ctDNA accurately predicted relapse, disease progression and mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in adjuvant setting in an Conclusions: This report suggests that ctDNA help monitor disease recurrence and identify genotypes in patients undergoing postoperative adjuvant EGFR-TKI therapy. More clinical researches are needed to support ctDNA is a promising tool for predicting disease progressive.

Indexed as

case reportCirculating tumor DNA (ctDNA)gefitinibosimertinibpostoperative adjuvant therapy

Identifiers

PMID36248329
PMCPMC9554680
OpenAlexW4296523041

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.